Everything tagged "ipo" across the TickerSpark archives.
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.
Freenome, Inc. Common stock (NASDAQ: FRNM) is expected to list on 2026-07-21, but the price range has not been disclosed yet. The company is going public through a SPAC merger with Perceptive Capital Solutions Corp., not a traditional IPO. Bulls will focus on the 2026 launch plan and large healthcare-investor PIPE; bears will focus on heavy losses and a still-unproven commercialization path.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Clinuvel Pharmaceuticals Limited American Depositary Shares are expected to list on NASDAQ on 2026-07-20, but the price range has not been disclosed. The setup looks more like an ADR listing upgrade than a classic new-money IPO, with an established profitable specialty pharma business behind it.
Harding, Loevner Funds, Inc. is expected to list on the NYSE on 2026-07-20, but the price range has not been disclosed. The filing trail points to a fund complex and reorganization activity, not a classic operating-company IPO. Bull case: a differentiated active-fund platform; bear case: this may not be a traditional IPO at all.
Gold Resource Corporation is expected to list on NYSE on 2026-07-20, but the price range has not been disclosed. The setup is a turnaround story built around higher metal prices and a cleaner balance sheet, while customer concentration and mine execution remain the key bears.
Tidal Trust IV (NYSE: AIHY) is expected to list on 2026-07-17, but the price range has not been disclosed. The filing trail points to an ETF trust, not a traditional operating-company IPO. Shareholders should watch whether this is really a fund launch story rather than a classic equity debut.
RMG ML Sports Holdings Rights (NASDAQ: SHOTR) is expected to list on 2026-07-17, with the price range not yet disclosed. This is a sports-focused SPAC, so the key question is whether the team can find a compelling target before the 21-month deadline. The bull case is sector focus and sponsor backing; the bear case is the usual SPAC dilution and deal-execution risk.
Safety Shot, Inc. (Nasdaq: SHOT) is expected to list on 2026-07-17, but the price range has not been disclosed. The company is already public, so the current filing is a resale/shelf setup rather than a fresh IPO. The bull case is a differentiated functional beverage with early revenue growth; the bear case is tiny sales, heavy losses, and dilution risk.
Southern Cross Acquisition I Corp. is expected to list on NASDAQ on 2026-07-17 in a $10.00 price range. The deal is for 10,000,000 shares, with a market cap of $115,000,000 if the full structure is sold. The bull case is a clean SPAC structure with a sponsor-backed trust; the bear case is the usual blank-check risk: no target yet and no operating business to underwrite.
QumulusAI, Inc. Common Stock (NASDAQ: QMLS) is expected to list on 2026-07-16. The company has not disclosed a price range, and this is a direct listing on Nasdaq rather than a traditional underwritten IPO. The setup favors investors who want AI infrastructure exposure, but shareholders should watch the customer concentration and share overhang risks closely.
Tidal Trust III is expected to list on the NYSE on 2026-07-16, but the price range has not been disclosed. The filing picture points to an ETF platform launch, not a traditional operating-company IPO. Bull case: a fast-moving thematic fund platform; bear case: no disclosed pricing, no IPO proceeds, and limited standalone financial disclosure.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime